ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics
Roche Leads But Rivals Could Have Efficacy Edge
Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.
You may also be interested in...
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.